Observational infant exploratory [14C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis

British Journal of Clinical Pharmacology

Volumn 80, Issue 1, 2015, Pages 157-167

  Garner, Colin R ^a,b   Park, Kevin B ^c   French, Neil S ^c   Earnshaw, Caroline ^c   Schipani, Alessandro ^c   Selby, Andrew M ^d   Byrne, Lindsay ^d   Siner, Sarah ^d   Crawley, Francis P ^e   Vaes, Wouter H J ^f   Van Duijn, Esther ^f   Deligt, Rianne ^f   Varendi, Heili ^g   Lass, Jane ^g   Grynkiewicz, Grzegorz ^h   Maruszak, Wioletta ^h   Turner, Mark A ^c  

^a UNIVERSITY OF YORK   (United Kingdom)

^b Garner Consulting   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^e Good Clinical Practice Alliance Europe   (Belgium)

^f TNO   (Netherlands)

^g TARTU UNIVERSITY HOSPITAL   (Estonia)

^h INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

Author keywords

accelerator mass spectrometry; exploratory clinical study; microdosing; paediatric pharmacokinetics; paracetamol

Indexed keywords

PARACETAMOL; PARACETAMOL C 14; UNCLASSIFIED DRUG; CARBON;

ACCELERATOR MASS SPECTROMETRY; AREA UNDER THE CURVE; ARTICLE; CHILD; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VOLUME OF DISTRIBUTION; BLOOD; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; NEWBORN; ORAL DRUG ADMINISTRATION;

ACETAMINOPHEN; ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; CARBON RADIOISOTOPES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MASS SPECTROMETRY;

EID: 84933042027     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12597     Document Type: Article

References (44)

1. Barker CI, Standing JF, Turner MA, McElnay JC, Sharland M,. Antibiotic dosing in children in Europe: can we grade the evidence from pharmacokinetic/pharmacodynamic studies-and when is enough data enough? Curr Opin Infect Dis 2012; 25: 235-42.
2. FDA, U.S. Guidance for industry, pediatric study plans:content of and process for submitting initial pediatric study plans and amended pediatric study plans 2013. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM360507.pdf.
3. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN,. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006; 45: 1077-97.
4. Leeder JS, Kearns GL, Spielberg SP, van den Anker J,. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol 2010; 50: 1377-87.
5. Hines RN,. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharm 2013; 452: 3-7.
6. Turner MA, Catapano M, Hirschfeld S, Giaquinto C, Global Research in Paediatrics. Paediatric drug development: the impact of evolving regulations. Adv Drug Deliv Rev 2014; 73: 2-13.
7. Leong R, Vieira ML, Zhao P, Mulugeta Y, Lee CS, Huang SM, Burckart GJ,. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin Pharmacol Ther 2012; 91: 926-31.
8. Johnson TN,. The problems in scaling adult drug doses to children. Arch Dis Child 2008; 93: 207-11.
9. Rodriguez W, Selen A, Avant D, Chaurasia C, Crescenzi T, Gieser G, Di Giacinto J, Huang S-M, Lee P, Mathis L,. Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics 2008; 121: 530-9.
10. Hines RN,. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 2008; 118: 250-67.
11. Guideline IM,. Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. ICH M3 (R2). International Conference on Harmonization. 2008.
12. Lappin G, Garner RC,. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2003; 2: 233-40.
13. Garner RC, Lappin G,. The phase 0 microdosing concept. Br J Clin Pharmacol 2006; 61: 367-70.
14. Garner RC,. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data. Bioanalysis 2010; 2: 429-40.
15. Lappin G, Noveck R, Burt T,. Microdosing and drug development: past, present and future. Expert Opin Drug Metab Toxicol 2013; 9: 817-34.
16. Yamane N, Tozuka Z, Sugiyama Y, Tanimoto T, Yamazaki A, Kumagai Y,. Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B 2007; 858: 118-28.
17. Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC,. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther 2006; 80: 203-15.
18. Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Brian Houston J, Oosterhuis B, Bjerrum OJ, Grynkiewicz G, Alder J, Rowland M, Garner C,. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. Eur J Pharmaceut Sci 2011; 43: 141-50.
19. Patel P, Mulla H, Tanna S, Pandya H,. Facilitating pharmacokinetic studies in children: a new use of dried blood spots. Arch Dis Child 2010; 95: 484-7.
20. Suyagh MF, Kole PL, Millership J, Collier P, Halliday H, McElnay JC,. Development and validation of a dried blood spot-LC-APCI-MS assay for estimation of canrenone in paediatric samples. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 769-76.
21. Abdel-Rahman S, Reed M, Wells T, Kearns G,. Considerations in the rational design and conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls. Clin Pharmacol Ther 2007; 81: 483-94.
22. Kaye B, Garner RC, Mauthe RJ, Freeman SP, Turteltaub KW,. A preliminary evaluation of accelerator mass spectrometry in the biomedical field. J Pharm Biomed Anal 1997; 16: 541-3.
23. Garner R,. Accelerator mass spectrometry in pharmaceutical research and development a new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 2000; 1: 205-13.
24. 14C)-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br J Clin Pharmacol 2013; 75: 763-8.
25. Graham RA, Lum BL, Morrison G, Chang I, Jorga K, Dean B, Shin YG, Yue Q, Mulder T, Malhi V, Xie M, Low JA, Hop CE,. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Dispos 2011; 39: 1460-7.
26. 14C-ursodiol in newborn infants using accelerator mass spectrometry. J Clin Pharmacol 2014 54: 1031-1037.
27. Mooij MG, van Duijn E, Knibbe CA, Windhorst AD, Hendrikse NH, Vaes WH, Spaans E, Fabriek BO, Sandman H, Grossouw D,. Pediatric microdose study of [14C] paracetamol to study drug metabolism using accelerated mass spectrometry: Proof of concept. Clin Pharmacokinet 2014; 53: 1045-51.
28. Wang C, Allegaert K, Tibboel D, Danhof M, van der Marel CD, Mathot RA, Knibbe CA,. Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults. J Clin Pharmacol 2014; 54: 619-29.
29. Association, WM. 2008. Declaration of Helsinki. Ethical principles for medical research involving human subjects. Available at http://www wma net/e/policy/b3 htm (last accessed 24 February 2015).
30. Available at ftp://ftp.cordis.europa.eu/pub/fp7/docs/ethical-considerations-paediatrics-en.pdf. Final 2008 (last accessed 24 February 2015).
31. van Duijn E, Sandman H, Grossouw D, Mocking JA, Coulier L, Vaes WH,. Automated combustion accelerator mass spectrometry for the analysis of biomedical samples in the low attomole range. Anal Chem 2014; 86: 7635-41.
32. Higton D, Young G, Timmerman P, Abbott R, Knutsson M, Svensson LD,. European Bioanalysis Forum recommendation: scientific validation of quantification by accelerator mass spectrometry. Bioanalysis. 2012; 4: 2669-79.
33. (ICRP), I. C. o. R. P. Limits for Intakes of Radionuclides by Workers ICRP Publication 30 (Part 1) Ann. ICRP 1979; 2: 3-4.
34. Manger RP,. A generic biokinetic model for Carbon-14. Radiat Prot Dosimetry 2011; 143: 42-51.
35. Gueorguieva I, Ogungbenro K, Graham G, Glatt S, Aarons L,. A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models. Comput Methods Programs Biomed 2007; 86: 51-61.
36. Wang C, Allegaert K, Tibboel D, Danhof M, van der Marel CD, Mathot RA, Knibbe CA,. Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults. J Clin Pharmacol 2013. doi: 10.1002/jcph.259 [Epub ahead of print].
37. Zhao W, Hill H, Le Guellec C, Neal T, Mahoney S, Paulus S, Castellan C, Kassai B, van den Anker JN, Kearns GL,. Population pharmacokinetics of ciprofloxacin in neonates and young infants less than 3 months of age. Antimicrobial Agents Chemother 2014; 58: 6572-80.
38. Zuppa AF, Hammer GB, Barrett JS, Kenney BF, Kassir N, Mouksassi S, Royal MA,. Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or Fever. J Pediatr Pharmacol Therapeut 2011; 16: 246-61.
39. Anderson BJ, Pons G, Autret-Leca E, Allegaert K, Boccard E,. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis1. Pediatr Anesth 2005; 15: 282-92.
40. Rowland M,. Microdosing: a critical assessment of human data. J Pharm Sci 2012; 101: 4067-74.
41. 1-receptor antagonists after an oral and intravenous microdose to human subjects. Br J Clin Pharmacol 2009; 67: 288-98.
42. Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, Garner C,. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Phramaceut Sci 2010; 40: 125-31.
43. Lappin G, Rowland M, Garner RC,. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin Drug Metab Toxicol 2006; 2: 419-27.
44. Jiang X, Zhao P, Barrett J, Lesko L, Schmidt S,. Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children. Clin Pharmacol Ther: pharmacometrics & systems pharmacology 2013; 2: e80.